Nanoparticle Albumin-bound Paclitaxel plus Carboplatin Therapy for Small Cell Lung Cancer Combined with Squamous Cell Carcinoma and Interstitial Lung Disease

被引：3

作者：

Azuma, Yuichiro ^{[1
]}

Tamiya, Motohiro ^{[1
]}

Shiroyama, Takayuki ^{[1
]}

Osa, Akio ^{[1
]}

Takeoka, Sawa ^{[1
]}

Morishita, Naoko ^{[1
]}

Suzuki, Hidekazu ^{[1
]}

Okamoto, Norio ^{[1
]}

Hirashima, Tomonori ^{[1
]}

Kawase, Ichiro ^{[1
]}

机构：

[1] Osaka Prefectural Med Ctr Resp & Allerg Dis, Dept Thorac Malignancy, Osaka, Japan

来源：

INTERNAL MEDICINE | 2015年 / 54卷 / 22期

关键词：

nab-paclitaxel; SCLC; interstitial lung disease; chemotherapy; CHEMOTHERAPY; COMBINATION;

D O I：

10.2169/internalmedicine.54.3243

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

It has recently been shown that nanoparticle albumin-bound paclitaxel (nab-PAC)+carboplatin (CBDCA) provides a favorable overall response rate in non-small cell lung cancer. This is the first case report of nab-PAC+CBDCA therapy in small cell lung cancer (SCLC). Our patient was a 72-year-old man with stage IV SCLC combined with squamous cell carcinoma and interstitial lung disease (ILD). We administered nab-PAC+CBDCA as a second-line chemotherapy. A partial response was evident after two cycles of chemotherapy, and no serious side effects occurred. The progression-free survival was 15 weeks. Second-line chemotherapy using nab-PAC+CBDCA was effective and well tolerated in an SCLC patient with ILD.

引用

页码：2911 / 2913

页数：3

共 7 条

[1] Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: A non-cross-resistant schedule [J].

Groen, HJM ;

Fokkema, E ;

Biesma, B ;

Kwa, B ;

van Putten, JWG ;

Postmus, PE ;

Smit, EF .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :927-932

[2] First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel [J].

Gupta, Neha ;

Hatoum, Hassan ;

Dy, Grace K. .

INTERNATIONAL JOURNAL OF NANOMEDICINE, 2014, 9 :209-221

[3] Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): A multicenter phase II study [J].

Kakolyris, S ;

Mavroudis, D ;

Tsavaris, N ;

Souglakos, J ;

Tsiafaki, P ;

Kalbakis, K ;

Agelaki, S ;

Androulakis, N ;

Georgoulias, V .

ANNALS OF ONCOLOGY, 2001, 12 (02) :193-197

[4] The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer [J].

Kenmotsu, Hirotsugu ;

Naito, Tateaki ;

Kimura, Madoka ;

Ono, Akira ;

Shukuya, Takehito ;

Nakamura, Yukiko ;

Tsuya, Asuka ;

Kaira, Kyoichi ;

Murakami, Haruyasu ;

Takahashi, Toshiaki ;

Endo, Masahiro ;

Yamamoto, Nobuyuki .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (07) :1242-1246

[5] Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial [J].

Socinski, Mark A. ;

Bondarenko, Igor ;

Karaseva, Nina A. ;

Makhson, Anatoly M. ;

Vynnychenko, Igor ;

Okamoto, Isamu ;

Hon, Jeremy K. ;

Hirsh, Vera ;

Bhar, Paul ;

Zhang, Hui ;

Iglesias, Jose L. ;

Renschler, Markus F. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2055-2062

[6] Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL(R)-free formulation of paclitaxel [J].

Stinchcombe, Thomas E. .

NANOMEDICINE, 2007, 2 (04) :415-423

[7] Effect of Topotecan as Second-Line Chemotherapy for Small Cell Lung Cancer Patients with Interstitial Lung Disease [J].

Suzuki, H. ;

Hirashima, T. ;

Kobayashi, M. ;

Sasada, S. ;

Okamoto, N. ;

Uehara, N. ;

Matsuura, Y. ;

Tamiya, M. ;

Morishita, N. ;

Higashiguchi, M. ;

Tsumori, T. ;

Kawase, I. .

JOURNAL OF CHEMOTHERAPY, 2011, 23 (06) :367-370

← 1 →